QuVa Pharma acquires CAPS' 503B product portfolio
QuVa Pharma acquired a range of essential medications from Central Admixture Pharmacy Services as CAPS exits the 503B sterile compounding business.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.